Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health.
However, for the treatment and diagnosis of various lung diseases, such as pneumonia …

Lipid nanoparticles (LNPs) largely rely on ionizable lipids to yield successful nucleic acid
delivery via electrostatic disruption of the endosomal membrane. Here, we report the …

The penetration behavior of nanoparticles in mucous depends on physicochemical
properties of the nanoparticles and the mucus microenvironment, due to particle–mucin …

Nanoparticles have opened a new perspective for oral drug delivery. However, nanoparticle
transport is strongly hindered by mucus and epithelial barriers before they can enter the …

Zwitterionic polymers have emerged as promising trans-mucus nanocarriers due to their
superior antifouling properties. However, for pH-sensitive zwitterionic polymers, the effect of …

Introduction: Airway mucus gel layer serves as a key delivery barrier that limits the
performance of inhaled drug delivery nanoparticles. Conventional nanoparticles are readily …

With specific and inherent mRNA cleaving activity, small interfering RNA (siRNA) has been
deemed promising therapeutics to reduce the exacerbation rate of asthma by inhibiting the …

In the lung, the airway epithelium produces secreted and tethered mucin biopolymers to
form a mucus hydrogel layer and a surface-attached polymer brush layer. These layers work …

Diseases of the pulmonary alveolus, such as pulmonary fibrosis, are leading causes of
morbidity and mortality, but exceedingly few drugs are developed for them. A major reason …